Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel Treatment for Brain Insulin Resistance and Hypoperfusion
NCT05153395Phase 1Suspended
- Sponsor
- University of Missouri
- Start
- Dec 2021
- Primary completion
- Jun 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1 trial of Generex Oral-lyn in insulin resistance (IR) and hypoperfusion (3 arms), sponsored by University of Missouri. Primary endpoint: Cerebral blood flow at 15 months. Started Dec 2021; status: suspended.
02
Drugs
Generex Oral-lyn
03
Conditions
insulin resistance (IR)hypoperfusion
Beyond the preview
Go deeper on NCT05153395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05153395.